Uploaded April 2019 | Updated November 2026, 3 hours ago
Patients in the U.S. are already confronted by the world’s longest climb to affordable biosimilar medicines. NAFTA 2.0 (USMCA) will increase obstacles for life-saving medicines, keeping prices high and out of reach for patients. Learn more at: bit.ly/NAFTA-Obstacles-blog
Patients in the U.S. are already confronted by the world’s longest climb to affordable biosimilar medicines. NAFTA 2.0 (USMCA) will increase obstacles for life-saving medicines, keeping prices high and out of reach for patients. Learn more at: bit.ly/NAFTA-Obstacles-blog










